Abstract Number: 2504 • ACR Convergence 2024
Polyarteritis Nodosa Associated with VEXAS Syndrome and Chronic Myelomonocytic Leukemia Compared with Primary Forms: A Case-Control Study
Background/Purpose: Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis affecting medium-sized vessels. It is a life-threatening disease without appropriate treatment. In 2024, approximately one quarter…Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…Abstract Number: 0737 • ACR Convergence 2024
Rurality and Delayed Diagnosis of Giant Cell Arteritis – a Single Center Experience
Background/Purpose: Giant Cell Arteritis (GCA) poses diagnostic challenges, especially in rural areas, where limited access to healthcare can delay diagnosis and worsen outcomes, a concern…Abstract Number: 0766 • ACR Convergence 2024
Neutrophil Transcriptomics in VEXAS Syndrome
Background/Purpose: Vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations of the ubiquitin-like modifier activating enzyme 1 (UBA1) gene and…Abstract Number: 1597 • ACR Convergence 2024
Baseline Glucocorticoid-Related Toxicity in Newly-Diagnosed and Relapsing ANCA-Associated Vasculitis
Background/Purpose: The ADVOCATE trial evaluated avacopan (a C5a receptor antagonist) as a replacement for a standard prednisone taper in the treatment of granulomatosis with polyangiitis…Abstract Number: 1630 • ACR Convergence 2024
Disease Manifestations, Diagnostic Findings, and Mortality of 120 Consecutive Patients Suspected of Giant Cell Arteritis – Results from a Hospital GCA Fast-Track Clinic
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis affecting the large vessels from aorta, its proximal branches, and the extra-cranial arteries. To avoid ischemic…Abstract Number: 2180 • ACR Convergence 2024
The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis
Background/Purpose: Vasculitis is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether the degree of this impact varies based…Abstract Number: 2505 • ACR Convergence 2024
C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?
Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…Abstract Number: 2647 • ACR Convergence 2024
Clinical Characteristics , Treatment Outcomes and Predictors of Mortality in a DADA2 Cohort of 101 Patients
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is a rare and potentially life threatening monogenic disorder characterized by systemic vasculitis, bone marrow failure, and immunodeficiency.…Abstract Number: 0742 • ACR Convergence 2024
Use of FDG-PET to Monitor Disease Activity in Patients with Giant Cell Arteritis on Tocilizumab
Background/Purpose: The optimal way to monitor disease activity in patients with GCA on tocilizumab remains uncertain. Acute phase reactants are not a reliable indicator of…Abstract Number: 0767 • ACR Convergence 2024
Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis
Background/Purpose: 18F-fluoro-deoxyglucose (FDG) is the current standard among radiotracers for PET/CT imaging of large vessel vasculitis (LVV) in giant cell arteritis (GCA), but its performance…Abstract Number: 1598 • ACR Convergence 2024
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…Abstract Number: 1632 • ACR Convergence 2024
Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?
Background/Purpose: Ultrasonography can measure vascular intimal-medial thickness (IMT) and delineate the degrees of stenosis in Takayasu arteritis (TAK). Further, higher IMT has been reported in…Abstract Number: 2191 • ACR Convergence 2024
Optimizing Inpatient Kawasaki Disease Care
Background/Purpose: Kawasaki Disease (KD), an acute pediatric vasculitis, requires inpatient management to prevent coronary artery disease. The Hospital for Sick Children (SickKids) sees about 100…Abstract Number: 2506 • ACR Convergence 2024
THP1-derived Macrophage Polarization in Takayasu Arteritis – Impact of Disease Status and Therapy
Background/Purpose: Macrophages play an important role in the pathophysiology of Takayasu arteritis (TAK) as granulomatous inflammation is typically found in affected arteries. The expression of…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 35
- Next Page »